PACIFIC and beyond – the promise of immunotherapy

Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).

If you would like to view this content you will need to register
(You will need your Username or E-mail along with your Password)
Click here to register or if you have forgotten your password.